1221 related articles for article (PubMed ID: 32552682)
21. Identification and validation of redox-immune based prognostic signature for hepatocellular carcinoma.
Tu K; Li J; Mo H; Xian Y; Xu Q; Xiao X
Int J Med Sci; 2021; 18(9):2030-2041. PubMed ID: 33850474
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Value of an m6A RNA Methylation Regulator-Based Signature in Patients with Hepatocellular Carcinoma.
Wu X; Zhang X; Tao L; Dai X; Chen P
Biomed Res Int; 2020; 2020():2053902. PubMed ID: 32733931
[TBL] [Abstract][Full Text] [Related]
23. Five metastasis-related mRNAs signature predicting the survival of patients with liver hepatocellular carcinoma.
Chen C; Liu YQ; Qiu SX; Li Y; Yu NJ; Liu K; Zhong LM
BMC Cancer; 2021 Jun; 21(1):693. PubMed ID: 34116652
[TBL] [Abstract][Full Text] [Related]
24. Construction of a lipid metabolism-related and immune-associated prognostic signature for hepatocellular carcinoma.
Hu B; Yang XB; Sang XT
Cancer Med; 2020 Oct; 9(20):7646-7662. PubMed ID: 32813933
[TBL] [Abstract][Full Text] [Related]
25. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of Notch receptors in postsurgical patients with hepatitis B virus-related hepatocellular carcinoma.
Yu T; Han C; Zhu G; Liao X; Qin W; Yang C; Liu Z; Su H; Liu X; Yu L; Liu Z; Lu S; Chen Z; Liang Y; Huang J; Qin X; Gui Y; Li J; Peng T
Cancer Med; 2017 Jul; 6(7):1587-1600. PubMed ID: 28568708
[TBL] [Abstract][Full Text] [Related]
27. Identification of Potential Hub Genes Related to Diagnosis and Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma via Integrated Bioinformatics Analysis.
Tang Y; Zhang Y; Hu X
Biomed Res Int; 2020; 2020():4251761. PubMed ID: 33376723
[TBL] [Abstract][Full Text] [Related]
28. The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy.
Zou R; Liu Y; Qiu S; Lu Y; Chen Y; Yu H; Zhu H; Zhu W; Zhu L; Feng J; Han J
Cancer Biomark; 2023; 38(4):551-566. PubMed ID: 38007640
[TBL] [Abstract][Full Text] [Related]
29. m
Li W; Liu J; Ma Z; Zhai X; Cheng B; Zhao H
Dis Markers; 2021; 2021():8859590. PubMed ID: 34234878
[TBL] [Abstract][Full Text] [Related]
30. N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma.
Yang K; Wang F; Li K; Peng G; Yang H; Xu H; Xiang Y; Sun H
Technol Cancer Res Treat; 2022; 21():15330338221085354. PubMed ID: 35422168
[No Abstract] [Full Text] [Related]
31. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
[TBL] [Abstract][Full Text] [Related]
32. Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients.
Zhu GQ; Yang Y; Chen EB; Wang B; Xiao K; Shi SM; Zhou ZJ; Zhou SL; Wang Z; Shi YH; Fan J; Zhou J; Liu TS; Dai Z
J Transl Med; 2019 Jun; 17(1):203. PubMed ID: 31215439
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of a m
Kong W; Li X; Xu H; Gao Y
Biomark Med; 2020 Sep; 14(13):1217-1228. PubMed ID: 33021385
[No Abstract] [Full Text] [Related]
34. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
[TBL] [Abstract][Full Text] [Related]
35. Multiple m
Qu N; Qin S; Zhang X; Bo X; Liu Z; Tan C; Wen G; Jiang H
BMC Cancer; 2020 Feb; 20(1):165. PubMed ID: 32111180
[TBL] [Abstract][Full Text] [Related]
36. The m6A/m5C/m1A regulator genes signature reveals the prognosis and is related with immune microenvironment for hepatocellular carcinoma.
Liu T; Sun L; Li ZZ; Yang K; Chen JM; Han XY; Qi LM; Zhou XG; Wang P
BMC Gastroenterol; 2023 May; 23(1):147. PubMed ID: 37170222
[TBL] [Abstract][Full Text] [Related]
37. A 4-gene prognostic signature predicting survival in hepatocellular carcinoma.
Chen PF; Li QH; Zeng LR; Yang XY; Peng PL; He JH; Fan B
J Cell Biochem; 2019 Jun; 120(6):9117-9124. PubMed ID: 30582205
[TBL] [Abstract][Full Text] [Related]
38. Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis.
Yan Z; He M; He L; Wei L; Zhang Y
Front Immunol; 2021; 12():723271. PubMed ID: 34925311
[TBL] [Abstract][Full Text] [Related]
39. Identification of molecular subtypes and prognostic signature for hepatocellular carcinoma based on genes associated with homologous recombination deficiency.
Lin H; Xie Y; Kong Y; Yang L; Li M
Sci Rep; 2021 Dec; 11(1):24022. PubMed ID: 34912005
[TBL] [Abstract][Full Text] [Related]
40. Seven-senescence-associated gene signature predicts overall survival for Asian patients with hepatocellular carcinoma.
Xiang XH; Yang L; Zhang X; Ma XH; Miao RC; Gu JX; Fu YN; Yao Q; Zhang JY; Liu C; Lin T; Qu K
World J Gastroenterol; 2019 Apr; 25(14):1715-1728. PubMed ID: 31011256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
